Prognostic Value of MiR-1826 in Prostate Cancer and Its Regulatory Effect on Tumor Progression

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2021 Aug 20

PMID 34413652

Authors

Yongguo Liu

Jing Liu

Xiancheng Han

Linkai Mou

Affiliations

Soon will be listed here.

Abstract

Purpose: miRNAs can act as oncogenes or tumor suppressors and participate in the development and progression of tumors, thus affecting the prognosis and survival of cancer patients. In this paper, we mainly studied the role of miR-1826 in prostate cancer.

Patients And Methods: The expression of miR-1826 was studied by quantitative real-time PCR (qRT-PCR). Kaplan-Meier curves were used to analyze the relationship between the expression of miR-1826 and the survival rate of PC patients. Cox regression analysis was used to study the risk factors affecting the prognosis of PC patients. PC cells were transfected with miR-1826 mimic, mimic negative control (mimic NC), miR-1826 inhibitor, or inhibitor NC. The effect of miR-1826 on the proliferation of PC cells was studied by the CCK-8 method and colony formation assay. Transwell assays were used to detect the effect of miR-1826 on the migratory and invasive abilities of tumor cells.

Results: The expression of miR-1826 in PC tissues was lower than that in adjacent normal tissues, and that the expression levels of miR-1826 in four PC cell lines were all lower than normal human prostate epithelial cell lines. Patients with low expression of miR-1826 had shorter overall survival compared with those with high expression. The downregulation of miR-1826 promoted PC cell proliferation, migration, and invasion.

Conclusion: In summary, the low expression of miR-1826 may promote the progression of PC, and the low expression of miR-1826 is also associated with a poor prognosis in PC patients.

References

Zhang L, Chen Y, Jia J, Zhu X, He Y, Wu L . MiR-27a promotes EMT in ovarian cancer through active Wnt/????-catenin signalling by targeting FOXO1. Cancer Biomark. 2019; 24(1):31-42. DOI: 10.3233/CBM-181229. View

Parashar D, Geethadevi A, McAllister D, Ebben J, Peterson F, Jensen D . Targeted biologic inhibition of both tumor cell-intrinsic and intercellular CLPTM1L/CRR9-mediated chemotherapeutic drug resistance. NPJ Precis Oncol. 2021; 5(1):16. PMC: 7925570. DOI: 10.1038/s41698-021-00152-9. View

Hirata H, Hinoda Y, Ueno K, Shahryari V, Tabatabai Z, Dahiya R . MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer. Carcinogenesis. 2011; 33(1):41-8. PMC: 3276333. DOI: 10.1093/carcin/bgr239. View

Xu B, Lu X, Zhao Y, Liu C, Huang X, Chen S . MicroRNA-135a induces prostate cancer cell apoptosis via inhibition of STAT6. Oncol Lett. 2019; 17(2):1889-1895. PMC: 6341792. DOI: 10.3892/ol.2018.9791. View

Adhami M, Haghdoost A, Sadeghi B, Malekpour Afshar R . Candidate miRNAs in human breast cancer biomarkers: a systematic review. Breast Cancer. 2017; 25(2):198-205. DOI: 10.1007/s12282-017-0814-8. View

Kiss O, Tokes A, Spisak S, Szilagyi A, Lippai N, Szekely B . Breast- and salivary gland-derived adenoid cystic carcinomas: potential post-transcriptional divergencies. A pilot study based on miRNA expression profiling of four cases and review of the potential relevance of the findings. Pathol Oncol Res. 2014; 21(1):29-44. DOI: 10.1007/s12253-014-9770-1. View

Cai J, Yang F, Zhan H, Situ J, Li W, Mao Y . RNA mA Methyltransferase METTL3 Promotes The Growth Of Prostate Cancer By Regulating Hedgehog Pathway. Onco Targets Ther. 2019; 12:9143-9152. PMC: 6842310. DOI: 10.2147/OTT.S226796. View

Yu H, Pan J, Guo Z, Yang C, Mao L . CART cell therapy for prostate cancer: status and promise. Onco Targets Ther. 2019; 12:391-395. PMC: 6322708. DOI: 10.2147/OTT.S185556. View

Wang Y, Zhang Q, Guo B, Feng J, Zhao D . miR-1231 Is Downregulated in Prostate Cancer with Prognostic and Functional Implications. Oncol Res Treat. 2019; 43(3):78-86. DOI: 10.1159/000504606. View

10.

Haj-Ahmad T, Abdalla M, Haj-Ahmad Y . Potential Urinary miRNA Biomarker Candidates for the Accurate Detection of Prostate Cancer among Benign Prostatic Hyperplasia Patients. J Cancer. 2014; 5(3):182-91. PMC: 3931266. DOI: 10.7150/jca.6799. View

11.

Hu Y, Yi B, He S, Gao L, Liu P, Wang L . Clinical Significance of miR-1826 as a Novel Prognostic Biomarker in Colorectal Cancer. Anticancer Agents Med Chem. 2015; 16(9):1109-16. DOI: 10.2174/1871520615666150507122434. View

12.

Peng P, Chen T, Wang Q, Zhang Y, Zheng F, Huang S . Decreased miR-218-5p Levels as a Serum Biomarker in Bone Metastasis of Prostate Cancer. Oncol Res Treat. 2019; 42(4):165-185. DOI: 10.1159/000495473. View

13.

Parashar D, Geethadevi A, Aure M, Mishra J, George J, Chen C . miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. Cell Rep. 2019; 29(13):4389-4406.e10. PMC: 7380555. DOI: 10.1016/j.celrep.2019.11.085. View

14.

Chen L, Hu W, Li G, Guo Y, Wan Z, Yu J . Inhibition of miR-9-5p suppresses prostate cancer progress by targeting StarD13. Cell Mol Biol Lett. 2019; 24:20. PMC: 6408831. DOI: 10.1186/s11658-019-0145-1. View

15.

Zhang X, Jin K, Luo J, Liu B, Xie L . MicroRNA-107 inhibits proliferation of prostate cancer cells by targeting cyclin E1. Neoplasma. 2019; 66(5):704-716. DOI: 10.4149/neo_2018_181105N825. View

16.

Ray J, Hoey C, Huang X, Jeon J, Taeb S, Downes M . MicroRNA‑198 suppresses prostate tumorigenesis by targeting MIB1. Oncol Rep. 2019; 42(3):1047-1056. PMC: 6667842. DOI: 10.3892/or.2019.7234. View

17.

Chen S, Lao J, Geng Q, Zhang J, Wu A, Xu D . A 3-MicroRNA Signature Identified From Serum Predicts Clinical Outcome of the Locally Advanced Gastric Cancer. Front Oncol. 2020; 10:565. PMC: 7323914. DOI: 10.3389/fonc.2020.00565. View

18.

Torbati P, Asadi F, Fard-Esfahani P . Circulating miR-20a and miR-26a as Biomarkers in Prostate Cancer. Asian Pac J Cancer Prev. 2019; 20(5):1453-1456. PMC: 6857886. DOI: 10.31557/APJCP.2019.20.5.1453. View

19.

Gao G, Xiu D, Yang B, Sun D, Wei X, Ding Y . miR-129-5p inhibits prostate cancer proliferation via targeting ETV1. Onco Targets Ther. 2019; 12:3531-3544. PMC: 6512784. DOI: 10.2147/OTT.S183435. View

20.

Bi C, Zhang G, Bai Y, Zhao B, Yang H . Increased expression of miR-153 predicts poor prognosis for patients with prostate cancer. Medicine (Baltimore). 2019; 98(36):e16705. PMC: 6738968. DOI: 10.1097/MD.0000000000016705. View